Citi Maintains 'Hold' Rating on Amgen (AMGN), Comments on FDA Briefing Documents
Tweet Send to a Friend
Citi maintains 'Hold' rating on Amgen (Nasdaq: AMGN), price target $55.
Citi analyst says, "Today's FDA briefing documents for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst says, "Today's FDA briefing documents for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
